Logo image of NNOX

NANO-X IMAGING LTD (NNOX) Stock Fundamental Analysis

NASDAQ:NNOX - Nasdaq - IL0011681371 - Common Stock - Currency: USD

5.15  +0.16 (+3.21%)

After market: 5.15 0 (0%)

Fundamental Rating

4

NNOX gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 102 industry peers in the Health Care Providers & Services industry. NNOX has a great financial health rating, but its profitability evaluates not so good. NNOX is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

NNOX had negative earnings in the past year.
NNOX had a negative operating cash flow in the past year.
In the past 5 years NNOX always reported negative net income.
NNOX had a negative operating cash flow in each of the past 5 years.
NNOX Yearly Net Income VS EBIT VS OCF VS FCFNNOX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

The Return On Assets of NNOX (-25.48%) is worse than 84.31% of its industry peers.
Looking at the Return On Equity, with a value of -28.30%, NNOX is doing worse than 67.65% of the companies in the same industry.
Industry RankSector Rank
ROA -25.48%
ROE -28.3%
ROIC N/A
ROA(3y)-32.63%
ROA(5y)-26.69%
ROE(3y)-37.21%
ROE(5y)-30.36%
ROIC(3y)N/A
ROIC(5y)N/A
NNOX Yearly ROA, ROE, ROICNNOX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 100 -100 200

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for NNOX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NNOX Yearly Profit, Operating, Gross MarginsNNOX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K -4K

More info and screens

8

2. Health

2.1 Basic Checks

NNOX does not have a ROIC to compare to the WACC, probably because it is not profitable.
NNOX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for NNOX has been increased compared to 5 years ago.
The debt/assets ratio for NNOX has been reduced compared to a year ago.
NNOX Yearly Shares OutstandingNNOX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
NNOX Yearly Total Debt VS Total AssetsNNOX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

An Altman-Z score of 6.48 indicates that NNOX is not in any danger for bankruptcy at the moment.
NNOX has a Altman-Z score of 6.48. This is amongst the best in the industry. NNOX outperforms 92.16% of its industry peers.
There is no outstanding debt for NNOX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 6.48
ROIC/WACCN/A
WACC8.97%
NNOX Yearly LT Debt VS Equity VS FCFNNOX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

A Current Ratio of 5.63 indicates that NNOX has no problem at all paying its short term obligations.
NNOX has a Current ratio of 5.63. This is amongst the best in the industry. NNOX outperforms 96.08% of its industry peers.
A Quick Ratio of 5.52 indicates that NNOX has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 5.52, NNOX belongs to the top of the industry, outperforming 96.08% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.63
Quick Ratio 5.52
NNOX Yearly Current Assets VS Current LiabilitesNNOX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 23.36% over the past year.
The Revenue has grown by 13.90% in the past year. This is quite good.
NNOX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 105.51% yearly.
EPS 1Y (TTM)23.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-27.78%
Revenue 1Y (TTM)13.9%
Revenue growth 3Y105.51%
Revenue growth 5YN/A
Sales Q2Q%25.16%

3.2 Future

NNOX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 34.80% yearly.
Based on estimates for the next years, NNOX will show a very strong growth in Revenue. The Revenue will grow by 91.32% on average per year.
EPS Next Y8.57%
EPS Next 2Y26.69%
EPS Next 3Y25.07%
EPS Next 5Y34.8%
Revenue Next Year91.44%
Revenue Next 2Y130.67%
Revenue Next 3Y93.57%
Revenue Next 5Y91.32%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
NNOX Yearly Revenue VS EstimatesNNOX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
NNOX Yearly EPS VS EstimatesNNOX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 4 6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

NNOX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NNOX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NNOX Price Earnings VS Forward Price EarningsNNOX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NNOX Per share dataNNOX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

NNOX's earnings are expected to grow with 25.07% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.69%
EPS Next 3Y25.07%

More info and screens

0

5. Dividend

5.1 Amount

NNOX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NANO-X IMAGING LTD

NASDAQ:NNOX (5/2/2025, 8:13:15 PM)

After market: 5.15 0 (0%)

5.15

+0.16 (+3.21%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)03-31 2025-03-31/bmo
Earnings (Next)05-13 2025-05-13/bmo
Inst Owners24.82%
Inst Owner Change-5.24%
Ins Owners4.54%
Ins Owner ChangeN/A
Market Cap328.36M
Analysts84
Price Target11.99 (132.82%)
Short Float %11.66%
Short Ratio3.68
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.32%
Min EPS beat(2)0.52%
Max EPS beat(2)32.13%
EPS beat(4)3
Avg EPS beat(4)12.35%
Min EPS beat(4)-4.07%
Max EPS beat(4)32.13%
EPS beat(8)5
Avg EPS beat(8)12.05%
EPS beat(12)6
Avg EPS beat(12)-6.6%
EPS beat(16)8
Avg EPS beat(16)-4.76%
Revenue beat(2)0
Avg Revenue beat(2)-19.22%
Min Revenue beat(2)-22.54%
Max Revenue beat(2)-15.9%
Revenue beat(4)0
Avg Revenue beat(4)-28.61%
Min Revenue beat(4)-43.3%
Max Revenue beat(4)-15.9%
Revenue beat(8)0
Avg Revenue beat(8)-24.28%
Revenue beat(12)0
Avg Revenue beat(12)-22%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-18.97%
PT rev (3m)-21.67%
EPS NQ rev (1m)-6.94%
EPS NQ rev (3m)-6.94%
EPS NY rev (1m)-4.26%
EPS NY rev (3m)-4.26%
Revenue NQ rev (1m)-31.93%
Revenue NQ rev (3m)-31.93%
Revenue NY rev (1m)-24.62%
Revenue NY rev (3m)-24.62%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 29.1
P/FCF N/A
P/OCF N/A
P/B 1.74
P/tB 2.76
EV/EBITDA N/A
EPS(TTM)-0.82
EYN/A
EPS(NY)-0.75
Fwd EYN/A
FCF(TTM)-0.62
FCFYN/A
OCF(TTM)-0.57
OCFYN/A
SpS0.18
BVpS2.97
TBVpS1.87
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -25.48%
ROE -28.3%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-32.63%
ROA(5y)-26.69%
ROE(3y)-37.21%
ROE(5y)-30.36%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 23.58%
Cap/Sales 24.52%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.63
Quick Ratio 5.52
Altman-Z 6.48
F-Score4
WACC8.97%
ROIC/WACCN/A
Cap/Depr(3y)37.93%
Cap/Depr(5y)1552.65%
Cap/Sales(3y)47.15%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)23.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-27.78%
EPS Next Y8.57%
EPS Next 2Y26.69%
EPS Next 3Y25.07%
EPS Next 5Y34.8%
Revenue 1Y (TTM)13.9%
Revenue growth 3Y105.51%
Revenue growth 5YN/A
Sales Q2Q%25.16%
Revenue Next Year91.44%
Revenue Next 2Y130.67%
Revenue Next 3Y93.57%
Revenue Next 5Y91.32%
EBIT growth 1Y-6.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y18.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y18.27%
OCF growth 3YN/A
OCF growth 5YN/A